Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Signs MOU to Mine High Grade Zone 2 at Cam Copper Mine (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > CXR-T 2016-03-29 DON'T BUY James Hodgins Took on
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by MustardTiger88on Mar 29, 2016 11:29pm
64 Views
Post# 24709610

RE:RE: CXR-T 2016-03-29 DON'T BUY James Hodgins Took on

RE:RE: CXR-T 2016-03-29 DON'T BUY James Hodgins Took on You already posted this in your attempt to spread fear.

FIVEBAGGER wrote:
FIVEBAGGER wrote:
  CXR-T   2016-03-29 DON'T BUY James Hodgins

Took on roughly 7 turns of debt, i.e. 7X their annual EBITDA, to make their most recent acquisition.  They are also seeing some problems in the US where they raised the price of their largest drug Donatel to something like 500%. That is likely to come under political pressure. Had been Short this, but it is getting to a level where it is more of a “stay away”.




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested